While the comparative advantages of tripeptides over larger peptides highlight their therapeutic potential, it is through specific examples that their true value becomes evident
Ubiquitous in living organisms, it occurs naturally in plants, fungi, and animal cells
Emerging data show that in patients with T2DM, the use of GLP-1 receptor agonists can significantly reduce the risk of esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancers, as well as meningioma and multiple myeloma (241)
Underscoring the potential health consequences from dosing errors and exposure to the wrong ingredients, in September 2025, the FDA reported receiving 1,150 reports of adverse events associated with compounded GLP-1 drugs, including hospitalizations and some deaths